Please login to the form below

Not currently logged in
Email:
Password:

Novartis divests cancer drugs to bring GSK deal to completion

Firms also collaborating on joint consumer health venture

Amgen's Kyprolis tops Velcade in myeloma trial

Amgen flagAmgen hoping to topple Takeda’s $2bn a year drug

Sanofi’s Lantus follow-up nears European approval

Sanofi receptionCHMP backing for Toujeo follows hot on the heels of its US approval by the FDA

Greater Manchester to control its share of the NHS budget

UK flagThe north-west English region accounts for 5% of the country's health spending

Jinarc backed for European approval in rare kidney disease

EU flagPositive opinion for Otsuka comes just before rare disease awareness day

UCB boosted by core medicines growth

UCBFirm’s new chief executive 'excited' by his company’s next batch of medicines

Sovaldi-Daklinza combo cures hep C in co-infected HIV patients

Phase III trial of BMS and Gilead antivirals cured 97% of patients

Gilead's Sovaldi wins NICE approval but faces access delay

Gilead SciencesThe Institute also recommends Janssen's hepatitis C drug Olysio

darwins medicineDoes 'trust leadership' feature in your strategy?

Pharma companies wanting to be more patient-focused will need to develop their people skills

Latest appointments

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Facilitate Ltd

Established in 2002, Facilitate is a global medical communications agency providing high-quality, creative services that focus on top-level opinion leader...

Latest intelligence

Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...
blog-icon_webinar_wow_c.png
E-detailing content wow factor in 2015
Many companies are reporting that the iPad novelty has worn off and healthcare professionals are demanding more than just another animation presented on a mobile device. So what exactly are...